Merck pursues $6B Terns Pharma acquisition to strengthen cancer pipeline. Pharmaceutical giant Merck is nearing completion of an approximately $6 billion all-cash acquisition of biotech firm Terns Pharmaceuticals, according to recent reports. The strategic move comes as Merck faces the impending patent expiration of its blockbuster cancer drug Keytruda, one of its most significant revenue drivers. By acquiring Terns, Merck aims to bolster its oncology portfolio and secure future growth in the competitive cancer treatment market. This deal represents a critical investment in maintaining market position and pipeline strength as the company navigates upcoming patent cliffs. The transaction underscores ongoing consolidation in the pharmaceutical sector as major players seek to acquire promising drug candidates and technologies.
